ES2897545T3 - 4-Oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de GPR139 - Google Patents

4-Oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de GPR139 Download PDF

Info

Publication number
ES2897545T3
ES2897545T3 ES19152036T ES19152036T ES2897545T3 ES 2897545 T3 ES2897545 T3 ES 2897545T3 ES 19152036 T ES19152036 T ES 19152036T ES 19152036 T ES19152036 T ES 19152036T ES 2897545 T3 ES2897545 T3 ES 2897545T3
Authority
ES
Spain
Prior art keywords
triazin
oxobenzo
acetamide
ethyl
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19152036T
Other languages
English (en)
Spanish (es)
Inventor
Stephan Hitchcock
Betty Lam
Holger Monenschein
Holly Reichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2897545T3 publication Critical patent/ES2897545T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES19152036T 2014-11-20 2015-11-19 4-Oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de GPR139 Active ES2897545T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25

Publications (1)

Publication Number Publication Date
ES2897545T3 true ES2897545T3 (es) 2022-03-01

Family

ID=55022667

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15816275T Active ES2734735T3 (es) 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139
ES19152036T Active ES2897545T3 (es) 2014-11-20 2015-11-19 4-Oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de GPR139

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15816275T Active ES2734735T3 (es) 2014-11-20 2015-11-19 Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139

Country Status (40)

Country Link
US (5) US9556130B2 (OSRAM)
EP (2) EP3221298B1 (OSRAM)
JP (2) JP6637501B2 (OSRAM)
KR (1) KR102582021B1 (OSRAM)
CN (2) CN107108531B (OSRAM)
AU (1) AU2015349866B2 (OSRAM)
CA (1) CA2968242C (OSRAM)
CL (1) CL2017001292A1 (OSRAM)
CO (1) CO2017005959A2 (OSRAM)
CR (1) CR20170275A (OSRAM)
CY (2) CY1122613T1 (OSRAM)
DK (2) DK3221298T3 (OSRAM)
DO (1) DOP2017000120A (OSRAM)
EA (1) EA033728B1 (OSRAM)
EC (1) ECSP17038999A (OSRAM)
ES (2) ES2734735T3 (OSRAM)
GE (1) GEP20196961B (OSRAM)
HR (2) HRP20191003T1 (OSRAM)
HU (2) HUE057451T2 (OSRAM)
IL (1) IL252311B (OSRAM)
JO (1) JO3719B1 (OSRAM)
LT (2) LT3536324T (OSRAM)
MA (1) MA40993B1 (OSRAM)
MD (1) MD3221298T2 (OSRAM)
MX (1) MX378158B (OSRAM)
MY (1) MY187423A (OSRAM)
NZ (1) NZ732208A (OSRAM)
PE (1) PE20170899A1 (OSRAM)
PH (1) PH12017500920A1 (OSRAM)
PL (2) PL3221298T3 (OSRAM)
PT (2) PT3536324T (OSRAM)
RS (2) RS59078B1 (OSRAM)
SG (1) SG11201704002UA (OSRAM)
SI (2) SI3221298T1 (OSRAM)
SM (2) SMT201900355T1 (OSRAM)
TN (1) TN2017000196A1 (OSRAM)
TW (1) TWI684590B (OSRAM)
UA (1) UA120375C2 (OSRAM)
UY (1) UY36406A (OSRAM)
WO (1) WO2016081736A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
WO2020081538A1 (en) 2018-10-16 2020-04-23 The Scripps Research Institute Methods related to opioid therapeutics
WO2020097609A1 (en) 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
KR20220063228A (ko) * 2019-09-16 2022-05-17 다케다 야쿠힌 고교 가부시키가이샤 아졸-융합된 피리다진-3(2h)-온 유도체
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
US20230227416A1 (en) * 2020-05-08 2023-07-20 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
WO2022058791A1 (en) 2020-09-21 2022-03-24 Takeda Pharmaceutical Company Limited Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
US20250163065A1 (en) * 2022-03-01 2025-05-22 Shanghaitech University Pyrrolotriazinone compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2023165262A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression
WO2025119351A1 (zh) * 2023-12-08 2025-06-12 深圳湾实验室 Gpr139激动剂
CN120424068A (zh) * 2024-02-02 2025-08-05 上海科技大学 稠杂环类化合物与其制备方法、药物组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) * 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
US4959368A (en) 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
WO2004108673A2 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
EP1651643A4 (en) 2003-07-31 2008-10-08 Irm Llc BICYCLIC COMPOUNDS AND COMPOSITIONS USED AS PDF INHIBITORS
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
CN101641358A (zh) * 2007-03-23 2010-02-03 霍夫曼-拉罗奇有限公司 氮杂-吡啶并嘧啶酮衍生物
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
HK1220622A1 (zh) 2013-03-14 2017-05-12 Janssen Pharmaceutica, N.V. Gpr139的生理性配体
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
TN2017000196A1 (en) 2018-10-19
KR102582021B1 (ko) 2023-09-22
MX378158B (es) 2025-03-10
US20200129518A1 (en) 2020-04-30
SMT201900355T1 (it) 2019-07-11
RS59078B1 (sr) 2019-09-30
SG11201704002UA (en) 2017-06-29
UA120375C2 (uk) 2019-11-25
EP3221298B1 (en) 2019-04-03
CR20170275A (es) 2017-10-30
CY1122613T1 (el) 2021-05-05
RS62563B1 (sr) 2021-12-31
SMT202200142T1 (it) 2022-05-12
US20170348319A1 (en) 2017-12-07
DK3221298T3 (da) 2019-06-24
SI3221298T1 (sl) 2019-10-30
CL2017001292A1 (es) 2018-02-16
HUE057451T2 (hu) 2022-05-28
PL3536324T3 (pl) 2022-02-07
TWI684590B (zh) 2020-02-11
MD3221298T2 (ro) 2019-10-31
EP3536324A1 (en) 2019-09-11
PH12017500920B1 (en) 2017-11-20
HRP20212009T1 (hr) 2022-04-01
PT3536324T (pt) 2021-11-10
TW201625566A (zh) 2016-07-16
CN112062730A (zh) 2020-12-11
WO2016081736A1 (en) 2016-05-26
PE20170899A1 (es) 2017-07-12
PL3221298T3 (pl) 2019-10-31
CO2017005959A2 (es) 2017-10-20
JP6918088B2 (ja) 2021-08-11
EP3221298A1 (en) 2017-09-27
JP2020063285A (ja) 2020-04-23
AU2015349866A1 (en) 2017-06-15
EA033728B1 (ru) 2019-11-20
SI3536324T1 (sl) 2021-12-31
HUE044145T2 (hu) 2019-09-30
US20190070187A1 (en) 2019-03-07
KR20170084324A (ko) 2017-07-19
AU2015349866B2 (en) 2020-12-03
CA2968242C (en) 2022-11-08
US9770450B2 (en) 2017-09-26
DK3536324T3 (da) 2021-10-25
LT3536324T (lt) 2021-12-10
EA201791096A1 (ru) 2017-11-30
JP2017535559A (ja) 2017-11-30
US9556130B2 (en) 2017-01-31
LT3221298T (lt) 2019-08-12
JP6637501B2 (ja) 2020-01-29
US11173161B2 (en) 2021-11-16
MY187423A (en) 2021-09-22
CY1124929T1 (el) 2023-01-05
GEP20196961B (en) 2019-03-25
CN107108531B (zh) 2020-10-20
US10159677B2 (en) 2018-12-25
MA40993B1 (fr) 2019-07-31
JO3719B1 (ar) 2021-01-31
US10561662B2 (en) 2020-02-18
IL252311B (en) 2020-07-30
US20160145218A1 (en) 2016-05-26
UY36406A (es) 2016-06-30
CN107108531A (zh) 2017-08-29
IL252311A0 (en) 2017-07-31
BR112017010311A2 (pt) 2017-12-26
MA40993A (fr) 2017-09-27
CN112062730B (zh) 2023-09-29
HRP20191003T1 (hr) 2019-08-23
ES2734735T3 (es) 2019-12-11
PH12017500920A1 (en) 2017-11-20
CA2968242A1 (en) 2016-05-26
US20170095480A1 (en) 2017-04-06
MX2017006448A (es) 2017-09-12
PT3221298T (pt) 2019-06-28
DOP2017000120A (es) 2017-06-15
ECSP17038999A (es) 2017-10-31
EP3536324B1 (en) 2021-10-06
NZ732208A (en) 2023-02-24

Similar Documents

Publication Publication Date Title
ES2897545T3 (es) 4-Oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de GPR139
CA2541618C (en) Rsv polymerase inhibitors
CN105732591B (zh) 取代的哌嗪化合物及其使用方法和用途
CN105517549B (zh) CaMKII抑制剂和其用途
CN106029075A (zh) 有机化合物
HK40013780A (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK40013780B (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
BR112017010311B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica compreendendo o mesmo, uso do referido composto ou sal farmaceuticamente aceitável do mesmo e combinação
HK1241859B (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
HK1241859A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
WO2025186751A1 (en) A quinoline based aniline nitrogen mustard conjugates as anti-cancer agent
CN107445981B (zh) 一种用于防治宫颈炎的活性化合物